Company Braeburn Inc.

Braeburn Inc is a pharmaceutical company, which focuses on the development and commercialization of long-acting medications for disorders of the central nervous system (CNS). The Company's implantable and injectable delivery mechanisms provide differentiated solutions for various diseases. The Company's therapeutic area is opioid addiction. The Company offers Probuphine. Its other therapeutic areas of focus include pain, schizophrenia and spasticity. The Company has approximately four additional late-stage product candidates in pipeline across different therapeutic areas, as well as approximately two earlier-stage product candidates. The Company's product portfolio combines approximately three primary delivery technologies with various compounds for the treatment of opioid addiction, pain, schizophrenia and spasticity: ProNeura implantable drug delivery technology, FluidCrystal injectable drug delivery platform and MedLaunch implant platform.